Currently, the first line of treatment for CKD anemia is erythropoietin-stimulating agents (ESAs) combined with iron therapy, which must be adequately metabolized to ensure the effectiveness of ESAs [147]. This evidence concerns the gene EPO and anemia (phenotype).